Key Takeaways
- Steriles is the story, and it is accelerating: Caplin Steriles matched its prior full-year sales in just nine months, driven by a new commercial line, and is on track to approach ₹300 crores for FY24.
- LATAM growth is normalizing, not stalling: Growth moderated to low double digits from 20%+ as management deliberately prioritizes profitability over top-line expansion on a now-larger base.
- Gross margins revert to a sustainable 55-56%: The Q2 spike to 60% was a one-off from favorable oncology institutional orders; management expects to hold around 55-56% going forward.
- The pipeline is broadening beyond LATAM injectables: Mexico filings, US front-end licensing, non-US dossier submissions, and a US distributor tie-up all point to a multi-geography, multi-format future, though revenue from these efforts is 12-18 months out.
- What to watch next quarter: Whether the one specific API arrives to hit the ₹300 crore Steriles target, the pace of US FDA approvals from the 14 products under active review, and any update on the delayed Vizag API facility.
Caplin Steriles: The Growth Engine
- Nine-month sales matched the prior full year: The addition of a third commercial line and the mid-October start of line five expanded capacity quickly, and that capacity was absorbed, producing 40% higher nine-month sales.
- Profitability is running above promise: Contribution margin hit 57.1% versus the 55% guided, and PAT margin reached 26.4% versus the 25% guided, though management cautions that one-off quarters can print higher.
- Capacity is now sufficient for four to five years: Line five more than doubled usable capacity, and over 70-80% of it is used for Caplin's own products rather than lower-margin CMO work.
- Phase three expansion is on hold: The shell is complete, but management slowed the project to assess utilization of existing lines before committing further capital.
- FY24 revenue hinges on one API: Management expects to reach close to or exactly ₹300 crores, with 99% confidence the needed API arrives within a week to 10 days; if it does not, the number will be very close.
- Next year's growth is promised but unquantified: Management is confident of "quite a reasonable growth" but refuses to put a number or percentage on it, citing multiple products expected to gain approval over the next few quarters.
C. C. Paarthipan: "Top line is vanity. Bottom line is sanity. Cash in the bank is king."
LATAM & Core Business Dynamics
- Growth moderated by design: LATAM growth decelerated to low double digits from 20%+ earlier, which management attributes to a base effect on larger volumes and a conscious shift toward profitability over top-line growth.
- Gross margin normalization is structural, not alarming: The drop from 60% in Q2 to 56% in Q3 reflects the absence of one-off high-margin oncology institutional orders; the nine-month average sits at 57%, and sustainable margins are pegged at 55-56%.
- Red Sea disruption was absorbed with inventory: Sufficient stocks were already positioned in warehouses near customers, and most consignments are not routed through the Red Sea; a 7-10 day delay and slight freight increase are manageable and may even help profit if prices are adjusted.
- FOB-to-CIF shift is a margin-neutral optimization: Moving to CIF for Guatemala lets the corporate group pool goods, optimize freight costs, and get faster container availability; goods reach a Guatemala warehouse and then travel by road to most countries.
- Expense discipline is paying off: After bringing channel partners into the fold two years ago, expenses are contained, and 75% of any increase in contribution margin now flows directly to PBT.
C. C. Paarthipan: "The smaller geographies that are considered insignificant by the major companies have become the center of gravity for our core business."
US & Regulated-Market Pipeline
- 14 products are under active FDA review: Most are expected to gain approval within the next 12 months, and the pipeline spans injectables, vials, ready-to-use bags, suspensions, emulsions, and ophthalmic products, with prefill syringes in the works.
- A top-three US distributor is now a partner: The distributor has tied up on about five products and is in active discussions for a private label on another four to five products, a significant validation of Caplin's manufacturing quality.
- The US front end is taking shape: CSL USA Inc is making good progress on state licensing and expects to hold licenses to distribute products on its own label in all 50 states within eight months, with an initial launch of 6-7 products in the first year.
- Non-US regulated markets are in the seeding phase: Filings have been made in Mexico, Canada, South Africa, and Australia, and management expects to see some non-US based revenue within the coming 18 months.
- Mexico is a priority beachhead: 24 products have been filed, 5 registrations have been received, and the target is to increase filings to at least 60-70 before the end of 2024.
Oncology & API: The Next Leg
- Oncology tablets and capsules are imminent: Commercial production starts before March 2024, with an Indian regulatory inspection scheduled imminently for the Caplin One facility.
- Oncology injectables are 8-9 months out: Machinery is on the way, and the injectable and API facilities will be completed in 9-10 months at the newly acquired Thervoy Kandigai site, where an 18.5-acre plot replaces a pilot plant that could not scale.
- The Vizag API facility is delayed but now staffed: An API expert who has filed 10 DMFs for niche products has joined with his team, and the focus is on completing the facility at the earliest, though no firm timeline is given.
- China outsourcing is a new sourcing strategy: Caplin has started outsourcing dossiers from reputed Chinese companies and plans to import biological products like Insulin in bulk for fill-and-finish, using a USFDA-approved CRO for clinical trials in an asset-light model.
Margins, Costs & Capital Allocation
- Contribution margin guidance is 55-56%: Management hopes to maintain this level for coming quarters, with the understanding that one-off quarters may print higher or lower.
- Steriles profitability fluctuates with investment: Filing fees run $240,000 per product, and R&D spend is increasing because Caplin files its own products rather than operating as a pure CMO, so quarterly PAT can move around.
- A large cash surplus is coming: After spending ₹300-500 crores over the next two years on existing projects, management expects ₹1,000 crores in surplus cash, at which point it will consider acquiring brands, companies for the domestic business, or distribution companies.
- Management refuses to segment core margins ex-Steriles: When asked if core business margins are returning to the pre-COVID 35% range, management deflected, arguing that netting off Steriles does not present the right picture and that the focus should be on whether the company is growing in the right direction.
D. Muralidharan: "About couple of years back when we took over the channel partners and then brought them into fold, there was some concern about the expenses going up and what not, it is all bearing fruits now and everybody is contributing and then we have been able to contain the expenses at manageable levels and that has shown in the flow of 75% in increasing contribution margin to the PBT directly."
Strategic Ambitions & New Bets
- Double-chamber PFS is a near-term niche: Machinery installation is set for March or April, with registration taking 6-9 months; only one multinational competitor exists in the Central American market.
- A Guatemala border warehouse will improve logistics: The new warehouse, closer to Mexico, addresses customer difficulty in reaching the capital and is expected to increase profitability and cash flow in coming years.
- Digitalization is underway at CSL: An e-log book will be completed by May or June, and BMR and BPR digitization will follow before the end of 2024, alongside cameras and biometric access control already installed.
- The five-year vision is facilities plus registrations: Management expects all facilities to be ready in two to three years and maximum registrations completed in the majority of countries in three to five years, with digitalized, CCTV-integrated operations.
- LATAM number-one ambition is explicit: Management claims that in five to six years, Caplin will be the number one company in LATAM, stating "in all humility I can claim that we can do it."
C. C. Paarthipan: "I am sure in five to six years from now we will be the number one company. In all humility I can claim that we can do it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Caplin Steriles FY24 revenue | Close to or exactly ₹300 crores, contingent on one API | FY24 (API arrival within 10 days of call) |
| US FDA product approvals | Most of 14 products under active review to be approved | Within next 12 months |
| US state licensing | Licenses to distribute on own label in all 50 states | Within next 8 months |
| US initial product launches | Around 6-7 products | Within first year of front-end operation |
| Oncology tablets/capsules commercialization | Commercial production start | Before March 2024 |
| Oncology injectables and API facility completion | Facility ready | 8-10 months from February 2024 |
| Double-chamber PFS market entry | Machinery installed March/April, then 6-9 months registration | Late 2024 / early 2025 |
| CSL e-log book completion | Digital log book operational | May or June 2024 |
| CSL BMR/BPR digitization | Full digitization | Before end of 2024 |
| Mexico filings target | Increase to at least 60-70 products filed | Before end of 2024 |
| Non-US regulated-market revenue | First revenue from Mexico, Canada, South Africa, Australia filings | Within coming 18 months |
| Contribution margin | Maintain around 55-56% | Coming quarters |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue (consolidated) | ₹1,290 cr (nine months), 15% growth YoY |
| Gross margin | 56% in Q3, down from 60% in Q2; 57.1% for nine months |
| PAT margin | 26.4% for nine months, above the promised 25% |
| PBT growth | ₹90 cr increase, with 75% of contribution increase flowing to PBT |
| Contribution margin | 57.1% for nine months, above the ~55% average promised |
| Liquid assets | ₹1,550 cr, exceeding nine-month revenue of ₹1,290 cr |
| Surplus cash | ~₹800 cr available for future capex and acquisitions |
| Caplin Steriles revenue | ~₹210 cr for nine months, on track toward ~₹300 cr for FY24 |
| Caplin Steriles EBITDA | ₹11.7 cr for Q3 FY24 |
| Caplin Steriles capacity utilization | 70–80% of usable capacity for own products; line five more than doubled capacity |
| Conventional business growth | ~11% YoY, moderated from earlier 17–18% on a larger base |
| CSL nine-month sales growth | 40% higher than previous year |
| Products under active FDA review | 14 products, most expected to be approved within 12 months |
| Mexico product filings | 24 filed, 5 registrations received; targeting 60–70 filings by end of 2024 |
| US front-end state licenses | Licenses to distribute on own label in all 50 states expected within 8 months |